Author: John Meady

Finance

Trending Tickers: Cubist Pharmaceuticals (NASDAQ:CBST), Cempra (NASDAQ:CEMP), Meridian Bancorp (NASDAQ:EBSB), Point.360 (NASDAQ:PTSX), Taminco (NYSE:TAM)

Cubist Pharmaceuticals Inc (CBST) announced yesterday, it is recalling 101 production lots of its antibiotic Cubicin (daptomycin injection) amid fear of glass particles being present in the drug. Cubicin, which is intravenously administered, is used to treat blood and skin infections. Cubist Pharmaceuticals Inc. (NASDAQ:CBST) belongs to Healthcare sector. Its net profit margin is 0.70% and weekly performance is 0.58%. On last trading day company … Continue reading Trending Tickers: Cubist Pharmaceuticals (NASDAQ:CBST), Cempra (NASDAQ:CEMP), Meridian Bancorp (NASDAQ:EBSB), Point.360 (NASDAQ:PTSX), Taminco (NYSE:TAM)

John Meady
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

China Telecom Reaps Efficiency Gains in 1Q After 3G Assets Acquisition

Carrier China Telecom CHA increased first-quarter revenue 15% year over year to CNY 78 billion ($12.6 billion) thanks to strong mobile service revenue and handset sales. EBITDA grew at a much faster pace of 36%, as the firm benefited from scale efficiencies on its 3G network after it acquired the assets from its parent at the end of December. We are maintaining our narrow economic … Continue reading China Telecom Reaps Efficiency Gains in 1Q After 3G Assets Acquisition

John MeadyLeave a comment